ELEMENTS OF ROBUST MODIFIED **OLIGONUCLEOTIDE EXTRACTION THROUGH SPE** Makda Araya, Abraham Finny, Balasubrahmanyam Addepalli and

Matthew Lauber

Waters Corporation

CONTACT INFORMATION: Makda_Araya@Waters.com

PURPOSE

Extraction and Quantification of Therapeutic Oligonucleotides (OTx) during Bioanalysis

Robust extraction of modified and unmodified oligonucleotides is essential for understanding their DMPK properties. Optimized sample preparation and carefully chosen ion exchange sorbent allow selective binding and purification of OTx.

METHODS

Materials – Sample Preparation

Ion exchange sorbents were screened with a mixture L-Tyrosine (Sigma P/N 93829), ssDNA 20-mer (Waters P/N 186009451) and Lipid Conjugated ASO (Waters P/N 186010774) using 1cc cartridge for SPE.

Rat plasma was subjected to RapiZyme[™] Proteinase K Digestion Module (Waters, P/N 186009450) under denaturing conditions.

Anion-exchange sorbent and SPE workflow



Ion Exchange sorbent contains mixed-mode (reversed-phase and a weak anion-exchange) functionalities suitable for various applications.



IP-RP-LC-UV assay for sorbent selection

Analyte mixture before and after SPE was subjected to ion pairing reversed phase liquid chromatography (IP-RP-LC-UV) analysis using ACQUITY[™] UPLC[™] and ACQUITY Premier Oligonucleotide BEH[™] C18, 130Å , 1.7μm, 2.1x50mm (Waters, P/N 186009484) Column at 60°C. Analyte signal at 260 nm was monitored using 0.1M 1:1 Triethylamine: Acetic Acid (TEAA) as mobile phase A and 0.1M TEAA in 50% Acetonitrile as mobile phase B with a gradient of 0.1% -100% B in 15 min at 0.6 mL/min flow rate.

IP-RP-LC-UV-MS assay for sorbent selection

Lipid conjugated ASO reference material was analyzed by IP-RP-LC-UV-MS using BioAccord[™] System involving ACQUITY UPLC System and RDa detector. About 15 pmol of Lipid Conjugated ASO was analyzed by using mobile phase A (0.1% DIPEA, 1% HFIP in 18.2 MΩ water) and mobile phase B (0.0375% DIPEA, 0.075% HFIP in 65:35 ACN:18.2 MΩ water). After 10 µL injection at 35% B, elution performed in 9 min to get 50%B followed by 90%B in 11 min and equilibration (35%B) for 8 min at 0.4 mL/min flowrate. Mass spectra were acquired in negative ion mode at 2 Hz scan rate, 40 V cone voltage and 0.8 kV capillary voltage.

Size Exclusion Chromatography of plasma samples, following treatment with Rapizyme Proteinase K under denaturing conditions, was done using ACQUITY Premier SEC 250Å 1.7µm 4.6 x 150 mm Column (Waters P/N186009963) and 2X PBS buffer at 0.2 mL/min flowrate.



inset.



24415



"ACQUITY, UPLC, BEH, BioAccord, RapiZyme, Oasis and OligoWorks are trademarks of Waters Technology Corporation"